Detalhe da pesquisa
1.
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
Cancer Sci
; 108(11): 2213-2220, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28837250
2.
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Cancer Sci
; 108(9): 1834-1842, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28665051
3.
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
J Neurooncol
; 122(2): 409-17, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25682091
4.
Phase 0 trials: an industry perspective.
Clin Cancer Res
; 14(12): 3683-8, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559583
5.
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
J Clin Oncol
; 20(8): 2171-80, 2002 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11956279
6.
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Clin Cancer Res
; 9(8): 2965-72, 2003 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12912943